[MOL] BUSULFEX INJECTION available in the US for Chronic Myelogenous Leu [00714] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] BUSULFEX INJECTION available in the US for Chronic Myelogenous Leukemia

Busulfex Injection Available In The U.S. For Chronic Myelogenous Leukemia

MINNEAPOLIS, MN -- Feb. 23, 1999 -- Orphan Medical, Inc.’s Busulfex(TM) (busulfan) Injection is now available in the United States for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML).

Orphan Medical also announced that Tzamal Pharma LTD has the right to distribute Busulfex in Israel. A privately owned company, Tzamal Pharma markets and distributes orphan drugs in Israel.

The most common adverse events in patients treated with Busulfex include profound myelosuppression in 100 percent of patients, nausea (97 percent, mild/moderate in 92 percent), stomatitis (97 percent, grade III in 26 percent), vomiting (95 percent, all mild/moderate) and anorexia (85 percent). The type of adverse events seen with Busulfex did not differ from those seen with oral busulfan in the transplant setting.

Warmly, lillian
We invite you to take a look at our Album.                                               
  ( Very informational, good tips, Molers pictures, art work and much more....